BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2024-09

195 industry Phase 2/3 trial readout(s) and 48 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2024-08 | 2024-10 →

FDA decision events

DateEventStatusCompanyDrugSource
2024-09-05FDA approvalapprovedTRAVERE TVTXFILSPARIApproved 2024-09-05: FILSPARI (NDA216403 SUPPL3)
2024-09-09FDA AdComheldIterum Therapeutics US Ltd.AdCom 2024-09-09: Antimicrobial Drugs Advisory Committee
2024-09-11FDA approvalapprovedJANSSEN BIOTECHTREMFYAApproved 2024-09-11: TREMFYA (BLA761061 SUPPL21)
2024-09-12FDA approvalapprovedGENENTECH INCTECENTRIQ HYBREZAApproved 2024-09-12: TECENTRIQ HYBREZA (BLA761347 ORIG1)
2024-09-12FDA approvalapprovedREGENERON PHARMACEUTICALS REGNDUPIXENTApproved 2024-09-12: DUPIXENT (BLA761055 SUPPL66)
2024-09-12FDA approvalapprovedARRAY BIOPHARMA INC ADBRAFTOVIApproved 2024-09-12: BRAFTOVI (NDA210496 SUPPL16)
2024-09-12FDA approvalapprovedARRAY BIOPHARMA INC ADMEKTOVIApproved 2024-09-12: MEKTOVI (NDA210498 SUPPL10)
2024-09-13FDA AdComheldIntercept Pharmaceuticals, Inc.AdCom 2024-09-13: Gastrointestinal Drugs Advisory Committee - sNDA 207999
2024-09-13FDA approvalapprovedELI LILLY AND CO LLYEBGLYSSApproved 2024-09-13: EBGLYSS (BLA761306 ORIG1)
2024-09-13FDA approvalapprovedUCB INCCIMZIAApproved 2024-09-13: CIMZIA (BLA125160 SUPPL275)
2024-09-13FDA approvalapprovedGENENTECH INCOCREVUS ZUNOVOApproved 2024-09-13: OCREVUS ZUNOVO (BLA761371 ORIG1)
2024-09-13FDA approvalapprovedVIVUS LLCQSYMIAApproved 2024-09-13: QSYMIA (NDA022580 SUPPL25)
2024-09-16FDA approvalapprovedINVAGEN PHARMSLANREOTIDE ACETATEApproved 2024-09-16: LANREOTIDE ACETATE (NDA215395 SUPPL7)
2024-09-17FDA approvalapprovedNOVARTIS NVSKISQALI FEMARA CO-PACKApproved 2024-09-17: KISQALI FEMARA CO-PACK (COPACKAGED) (NDA209935 SUPPL27)
2024-09-17FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2024-09-17: KEYTRUDA (BLA125514 SUPPL161)
2024-09-17FDA approvalapprovedGENENTECH INCEVRYSDIApproved 2024-09-17: EVRYSDI (NDA213535 SUPPL13)
2024-09-17FDA approvalapprovedASTRAZENECA AB AZNFASENRAApproved 2024-09-17: FASENRA (BLA761070 SUPPL21)
2024-09-17FDA approvalapprovedNOVARTIS NVSKISQALIApproved 2024-09-17: KISQALI (NDA209092 SUPPL18)
2024-09-18FDA AdComheldAdCom 2024-09-18: Pediatric Advisory Committee
2024-09-19FDA approvalapprovedJANSSEN BIOTECHRYBREVANTApproved 2024-09-19: RYBREVANT (BLA761210 SUPPL4)
2024-09-20FDA AdComheldAdCom 2024-09-20: Vaccines and Related Biological Products Advisory Committee
2024-09-20FDA approvalapprovedUCB INCBIMZELXApproved 2024-09-20: BIMZELX (BLA761151 SUPPL7)
2024-09-20FDA approvalapprovedUCB INCBIMZELXApproved 2024-09-20: BIMZELX (BLA761151 SUPPL5)
2024-09-20FDA approvalapprovedUCB INCBIMZELXApproved 2024-09-20: BIMZELX (BLA761151 SUPPL6)
2024-09-20FDA approvalapprovedZEVRA DENMARK ZVRAMIPLYFFAApproved 2024-09-20: MIPLYFFA (NDA214927 ORIG1)
2024-09-20FDA approvalapprovedGENENTECHACTEMRAApproved 2024-09-20: ACTEMRA (BLA125276 SUPPL144)
2024-09-20FDA approvalapprovedVIIV HLTHCAREAPRETUDEApproved 2024-09-20: APRETUDE (NDA215499 SUPPL8)
2024-09-20FDA approvalapprovedGENENTECHACTEMRAApproved 2024-09-20: ACTEMRA (BLA125472 SUPPL56)
2024-09-20FDA approvalapprovedSANOFI AVENTIS US SNYSARCLISAApproved 2024-09-20: SARCLISA (BLA761113 SUPPL14)
2024-09-20FDA approvalapprovedVIIV HLTHCAREVOCABRIAApproved 2024-09-20: VOCABRIA (NDA212887 SUPPL9)
2024-09-20FDA approvalapprovedVIIV HLTHCAREVOCABRIAApproved 2024-09-20: VOCABRIA (NDA212887 SUPPL10)
2024-09-20FDA approvalapprovedVIIV HLTHCARECABENUVA KITApproved 2024-09-20: CABENUVA KIT (NDA212888 SUPPL15)
2024-09-24FDA approvalapprovedINTRABIOAQNEURSAApproved 2024-09-24: AQNEURSA (NDA219132 ORIG1)
2024-09-25FDA approvalapprovedASTRAZENECA AZNTAGRISSOApproved 2024-09-25: TAGRISSO (NDA208065 SUPPL33)
2024-09-26FDA AdComheldAdCom 2024-09-26: Oncologic Drugs Advisory Committee
2024-09-26FDA approvalapprovedBRISTOL-MYERS BMYCOBENFYApproved 2024-09-26: COBENFY (NDA216158 ORIG1)
2024-09-27FDA approvalapprovedFRESENIUS KABI USAOTULFIApproved 2024-09-27: OTULFI (BLA761379 ORIG1)
2024-09-27FDA approvalapprovedREGENERON PHARMACEUTICALS REGNDUPIXENTApproved 2024-09-27: DUPIXENT (BLA761055 SUPPL64)
2024-09-27FDA approvalapprovedGE HLTHCAREFLYRCADOApproved 2024-09-27: FLYRCADO (NDA215168 ORIG1)
2024-09-27FDA approvalapprovedELI LILLY AND CO LLYRETEVMOApproved 2024-09-27: RETEVMO (NDA218160 SUPPL3)
2024-09-27FDA approvalapprovedELI LILLY AND CO LLYRETEVMOApproved 2024-09-27: RETEVMO (NDA218160 SUPPL2)
2024-09-27FDA approvalapprovedSUN PHARMBYNFEZIA PENApproved 2024-09-27: BYNFEZIA PEN (NDA213224 ORIG1)
2024-09-27FDA approvalapprovedELI LILLY AND CO LLYRETEVMOApproved 2024-09-27: RETEVMO (NDA213246 SUPPL13)
2024-09-27FDA approvalapprovedELI LILLY AND CO LLYRETEVMOApproved 2024-09-27: RETEVMO (NDA213246 SUPPL11)
2024-09-30Complete response letterapproved sinceCelltrion Inc.CRL 2024-09-30: Celltrion Inc. BLA 761338
2024-09-30FDA approvalapprovedACADIA PHARMS INC ACADDAYBUEApproved 2024-09-30: DAYBUE (NDA217026 SUPPL1)
2024-09-30FDA approvalapprovedIDORSIAQUVIVIQApproved 2024-09-30: QUVIVIQ (NDA214985 SUPPL11)
2024-09-30FDA approvalapprovedIDORSIAQUVIVIQApproved 2024-09-30: QUVIVIQ (NDA214985 SUPPL10)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2024-09 est.P1/P2CelaCare Technologies, Inc.NCT03250923 CelAgace™ OraRinse Solution for Treatment of CandidiasisCandidiasis, Oralunknown15
2024-09 est.P2ISA PharmaceuticalsNCT03669718 A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPCSquamous Cell Carcinoma of the Oropharynx; HPV16 Positiveunknown194
2024-09 est.P2AphiosNCT03806478 Study of APH-1105 in Patients With Mild to Moderate Alzheimer's DiseaseDementia; Alzheimer Disease 1; Alzheimer Disease 2; Alzheimer Disease 3unknown60
2024-09 est.P3Cirius Therapeutics, Inc.NCT03970031 A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASHType2 Diabetes; NASH - Nonalcoholic Steatohepatitis; Nonalcoholic Steatohepatitis; Non-Alcoholic Fatunknown1800
2024-09 est.P2APRINOIA Therapeutics, LLCNCT04141150 Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy SubjectsAlzheimer's Disease; Mild Cognitive Impairment Due to Alzheimer's Disease; Healthy Volunteersunknown130
2024-09 est.P1/P2Sorrento Therapeutics, Inc.NCT04316442 Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL AmyloidosisLight Chain (AL) Amyloidosisunknown60
2024-09 est.P2Philogen S.p.A.NCT04362722 Intratumoral Administration of Daromun in Non-melanoma Skin Cancer PatientsCarcinoma, Basal Cell; Carcinoma, Cutaneous Squamous Cellunknown40
2024-09 est.P2Celltex Therapeutics CorporationNCT04428801 Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19COVID-19unknown200
2024-09 est.P1/P2AVEM HealthCareNCT04798716 The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19Covid19; Novel Coronavirus Pneumonia; Acute Respiratory Distress Syndromeunknown55
2024-09 est.P2Audion Therapeutics BVNCT05061758 A Trial of LY3056480 in Patients With SNLHSensorineural Hearing Losswithdrawn
2024-09 est.P2Poxel SANCT05146284 Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)Adrenomyeloneuropathywithdrawn
2024-09 est.P2Poxel SANCT05200104 Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)ALD (Adrenoleukodystrophy)withdrawn
2024-09 est.P2Engrail Therapeutics INCNCT05481905 ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal SeizuresFocal Epilepsywithdrawn
2024-09 est.P2AlgoTherapeutixNCT05593614 Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)Chemotherapy-induced Peripheral Neuropathyactive not recruiting276
2024-09 est.P1/P2GreenLight Biosciences, Inc. GLRENCT05602961 A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine BoosterCOVID-19withdrawn
2024-09 est.P2OrsoBio, IncNCT05665751 A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin ResistanceInsulin Resistanceunknown76
2024-09 est.P3BiocadNCT05800327 A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously aRheumatoid Arthritisactive not recruiting261
2024-09 est.P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05859373 To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent ChemoraNon-small Cell Lung Cancerunknown78
2024-09 est.P2Repurposed Therapeutics, Inc.NCT05886660 Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor PerformanceMotion Sickness, Space; Motion Sickness; Sea Sicknessunknown30
2024-09 est.P1/P2Shanghai Cell Therapy Group Co.,LtdNCT05944185 Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid TumorsAdvanced Solid Tumorunknown42
2024-09 est.P2Carmell Therapeutics CorporationNCT06258499 Bone Healing Accelerant (BHA) Versus Autologous Bone Grafting (ABG) for Hindfoot or Ankle ArthrodesisFoot Deformitieswithdrawn
2024-09 est.P1/P2LiteVax BVNCT06294262 Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza VaccineVaccination Reactionunknown84
2024-09 est.P2Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdNCT06367114 Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System InfiltratioRelapsed or Refractory Acute Lymphoblastic Leukemiaunknown50
2024-09 est.P2Hanlim Pharm. Co., Ltd.NCT06434792 Study to Evaluate Efficacy and Safety of Bronpass Tab. in Patients With Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Diseaseunknown96
2024-09 est.P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06566248 A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With PrimaryChronic Hepatitis Bunknown90
2024-09 est.P3Clover Biopharmaceuticals AUS Pty CBPHFNCT06567457 Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in AdultsCOVID-19withdrawn
2024-09-01 est.P1/P2Ascentage Pharma Group Inc. AAPGNCT04942067 APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple MyelomaMultiple Myeloma; Amyloidosisunknown108
2024-09-01P1/P2GAIA BioMedicine Inc. GAIANCT05207371 Clinical Trial of GAIA-102 for Advanced and Relapse NSCLCCell Therapy; NSCLCterminated22
2024-09-01 est.P3Qilu Pharmaceutical Co., Ltd.NCT05446883 QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical CancerMETASTATIC CERVICAL CANCERunknown498
2024-09-01 est.P2SpineX Inc.NCT05720208 Spinal Cord Innovation in Pediatrics (SCiP) to Treat SensoriMotor Function in Children Cerebral Palsy: Protocol for a Randomized Controlled TrialCerebral Palsyunknown60
2024-09-01 est.P3CSPC Ouyi Pharmaceutical Co., Ltd.NCT05753865 A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)Advanced Breast Cancerunknown454
2024-09-01P2MedRegen LLCNCT05844527 Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty PatientsWound of Skin; Abdominal Woundcompleted10
2024-09-02P1/P2GlaxoSmithKlineNCT05480800 A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid FeverSalmonella Infectionscompleted155
2024-09-02P2Qilu Pharmaceutical Co., Ltd.NCT06058000 A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic DermatitisAtopic Dermatitiscompleted120
2024-09-02P2Cutia Therapeutics(Wuxi)Co.,LtdNCT06194188 A Phase 2 Clinical Study of CU-20401Efficacy and Safetycompleted108
2024-09-03P1/P2Achilles Therapeutics UK LimitedNCT03997474 ATL001 in Patients With Metastatic or Recurrent MelanomaMelanomaterminated13
2024-09-03P3Hoffmann-La RocheNCT04777201 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular DegenerationNeovascular Age-related Macular Degenerationcompleted1036
2024-09-03P2Bausch Health Americas, Inc.NCT04857112 Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative ColitisUlcerative Colitiscompleted322
2024-09-03P3Prokidney PROKNCT05286853 A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney DiseaseType 2 Diabetes Mellitus; Chronic Kidney Diseaseswithdrawn
2024-09-03P3AbbVie ABBVNCT05454033 A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around Perioral Linescompleted198
2024-09-03P2Insmed Incorporated INSMNCT06101823 Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)Atopic Dermatitiscompleted50
2024-09-04P2Mirum Pharmaceuticals, Inc. MIRMNCT04168385 MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat StudyCholestatic Liver Diseasecompleted52
2024-09-04P2Lumos PharmaNCT04614337 Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)Growth Hormone Deficiencycompleted104
2024-09-04P2BeiGeneNCT05014815 Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung CancerLocally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC); Nonsmall Cell Lung completed272
2024-09-04P2Supernus Pharmaceuticals, Inc. SUPNNCT05107128 A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)Huntington's Diseasecompleted189
2024-09-04P1/P2Artax Biopharma IncNCT05725057 Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque PsoriasisPsoriasis; Plaque Psoriasiscompleted31
2024-09-04P3Alfasigma S.p.A.NCT05785611 A Study Evaluating the Effect of Filgotinib in Participants With Active Axial SpondyloarthritisAxial Spondyloarthritisactive not recruiting495
2024-09-04P3Dong-A ST Co., Ltd.NCT05842408 Clinical Trial of DA-5212 in Patients with Functional DyspepsiaFunctional Dyspepsiacompleted384
2024-09-04P2Neurogastrx, Inc.NCT06500429 A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) AgonistOverweight and Obesity; Healthycompleted120
2024-09-05P3Merck Sharp & Dohme LLC MRKNCT04738487 Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive MetastatLung Neoplasms; Non-Small-Cell Lung Carcinomaterminated1264
2024-09-05P3Eli Lilly and Company LLYNCT05074420 A Study of Baricitinib (LY3009104) in Children With COVID-19Covid19; Corona Virus Infectionterminated6
2024-09-05P3Takeda TAKNCT05707351 A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia AHemophilia Acompleted37
2024-09-05P2Alto Neuroscience ANRONCT05712187 Phase 2b Study of ALTO-100 in MDDMajor Depressive Disordercompleted301
2024-09-05P3Boryung Pharmaceutical Co., LtdNCT05930028 A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary HypercholesterolemiaEssential Hypertension; Primary Hypercholesterolemiacompleted148
2024-09-05P2/P3Atom Therapeutics Co., LtdNCT06276556 Extension Study of ABP-671 in Participants With GoutGoutterminated43
2024-09-06P3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02446132 Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeAgitation in Patients With Dementia of the Alzheimer's Typeterminated1197
2024-09-06P2Hutchmed HCMNCT04579679 Open-Label Surufatinib in European Patients With NETNeuroendocrine Tumours; Neuroendocrine Tumour of the Lung; Small Intestinal NETterminated78
2024-09-06P2UCB Biopharma SRLNCT04658186 A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's DiseaseEarly-stage Parkinson's Diseasecompleted496
2024-09-06P3Jiangsu HengRui Medicine Co., Ltd.NCT05009290 A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical ProstatectomyPatients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radicalterminated391
2024-09-06P1/P2Hutchmed HCMNCT05077384 Open-label Study of Surufatinib in Japanese PatientsNeuroendocrine Tumors; Non-hematologic Malignancycompleted36
2024-09-06P1/P2MeiraGTx, LLC MGTXNCT05603312 A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's ParticipantsParkinson's Diseasecompleted14
2024-09-06P3Sanofi SNYNCT05878093 Dupilumab in Chinese Adult Participants With CRSwNPChronic Rhinosinusitis With Nasal Polypscompleted63
2024-09-06P3Sinovac (Dalian) Vaccine Technology Co., Ltd.NCT06314724 Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the PhilippinesVaricellacompleted642
2024-09-09P3SFJ Pharmaceuticals, Inc.NCT04286438 Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive ProcedureHemorrhage; Urgent Surgery; Invasive Procedurecompleted226
2024-09-09 est.P2Sunshine Lake Pharma Co., Ltd. SBFMNCT04992858 Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping MutationsAdvanced NSCLCwithdrawn
2024-09-09P3AstraZeneca AZNNCT05274815 Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe AsthmaAsthmacompleted305
2024-09-09P3Marinus PharmaceuticalsNCT05323734 Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related EpilepsyTuberous Sclerosis Complexcompleted129
2024-09-09P2Fujian Shengdi Pharmaceutical Co., Ltd.NCT06054698 Efficacy and Safety of HRS9531 Injections in Overweight or Obese SubjectsOverweight or Obesitycompleted61
2024-09-10P33D Medicines (Sichuan) Co., Ltd.NCT03478488 Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTCBiliary Tract Neoplasmscompleted472
2024-09-10P2/P3Sage TherapeuticsNCT05366751 A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential TremorEssential Tremorterminated97
2024-09-10P3Daewoong Pharmaceutical Co. LTD.NCT05643508 A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and HyperlipidemiHypertension; Hyperlipidemiascompleted214
2024-09-10P2Medibiofarma S.L.NCT05940558 Safety and Efficacy of MBF-118 in Patients with Crohn DiseaseCrohn Diseasecompleted10
2024-09-10P2Colgate Palmolive CLNCT06565897 Clinical Investigation to Assess the Efficacy of Manual Toothbrushes in the Reduction of Plaque and Gingivitis.Plaque, Dental; Gingivitiscompleted84
2024-09-11P3BioRay Pharmaceutical Co., Ltd.NCT04514419 Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + DocetaxelBreast Canceractive not recruiting408
2024-09-11P2Hoffmann-La RocheNCT04777331 A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's DiseaseParkinsons Diseaseactive not recruiting586
2024-09-11P3Biogen BIIBNCT05083923 A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)Relapsing Forms of Multiple Sclerosiscompleted136
2024-09-11 est.P3Lambda Therapeutic Research Ltd.NCT05419427 Denosumab Biosimilar Injection in Post Menopausal Women With OsteoporosisOsteoporosis, Postmenopausalunknown552
2024-09-11P3BioCryst Pharmaceuticals BCRXNCT05453968 Berotralstat Treatment in Children With Hereditary AngioedemaHereditary Angioedema; Pediatricactive not recruiting29
2024-09-12P2/P3Neurim Pharmaceuticals Ltd.NCT05267535 Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's DiseaseAlzheimer's Diseaseterminated216
2024-09-12P3AbbVie ABBVNCT05316233 JUVÉDERM® VOLITE™ XC Injectable Gel for Improvement in Neck AppearanceNeck Linescompleted159
2024-09-12P2Jiangsu HengRui Medicine Co., Ltd.NCT05522439 A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil PhenotypeAsthma With Eosinophilic Phenotypecompleted85
2024-09-12P1/P2Bristol-Myers Squibb BMYNCT05543629 A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung CancerAdvanced Solid Tumors; Non-small Cell Lung Cancerterminated36
2024-09-12P1/P2Oncternal Therapeutics, IncNCT05588440 A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell MalignanciesRelapsed/Refractory Aggressive B-Cell Malignanciesterminated9
2024-09-12P1/P2Oncternal Therapeutics, IncNCT05917470 A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.Metastatic Castration-resistant Prostate Cancerterminated21
2024-09-13P2AstraZeneca AZNNCT03334617 Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyNon-Small Cell Lung Canceractive not recruiting528
2024-09-13P1/P2Arvinas Estrogen Receptor, Inc. ARVNNCT04072952 A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast CancerBreast Cancercompleted219
2024-09-13P2/P3argenx ARGXNCT05267600 A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous PemphigoidBullous Pemphigoidcompleted98
2024-09-13P2/P3Bristol-Myers Squibb BMYNCT05470985 A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Crohn Diseaseterminated5
2024-09-13P2Biotheus Inc.NCT05756972 A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLCNSCLCactive not recruiting64
2024-09-13P2Shanghai Pharmaceuticals Holding Co., LtdNCT05770609 A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative ColitisMild to Moderate Ulcerative Colitiscompleted53
2024-09-13P3AbbVie ABBVNCT06174688 A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult ParticipantsForehead Linescompleted140
2024-09-13P2Pfizer PFENCT06237049 A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy AdultsInfluenza, Human; SARS-CoV-2 Infection; COVID-19completed644
2024-09-13P2BrightGene Bio-Medical Technology Co., Ltd.NCT06973681 A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese SubjectsOverweight or Obesitycompleted120
2024-09-13P1/P2Applied CognitionNCT07432997 Pharmacological Enhancement of Glymphatic Function in HumansAlzheimer Diseasecompleted31
2024-09-15P3Amgen AMGNNCT05724199 A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe AtAtopic Dermatitiscompleted746
2024-09-15 est.P2DermBiont, Inc.NCT06108024 A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic KeratosisSeborrheic Keratosisunknown60
2024-09-15P3Shanghai Institute Of Biological ProductsNCT06399003 Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 MonthsMeasles-Mumps-Rubellacompleted1200
2024-09-16P2Oculis OCSNCT04762017 OCS-05 in Patients With Optic NeuritisOptic Neuritiscompleted36
2024-09-16P1/P2Criterium, Inc.NCT04791384 Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast CancerBreast Cancerterminated5
2024-09-16P2ImmuneSensor Therapeutics Inc.NCT05846646 Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCCOligometastatic Diseaseterminated6
2024-09-16P3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT05919823 A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 SchizophreniaSchizophreniacompleted202
2024-09-16P3Cipla Ltd.NCT06154304 BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild AsthmaBronchial Asthmacompleted120
2024-09-17P1/P2Miltenyi Biomedicine GmbHNCT03664635 MB-CART20.1 LymphomaRelapsed or Refractory B-cell Non-Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; B-cell Lymphoma Refraccompleted10
2024-09-17P2ShionogiNCT04215991 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric ParticipantsGram-negative Bacterial Infections; Hospital Acquired Bacterial Pneumonia (HABP); Complicated Urinarcompleted91
2024-09-17P3Boehringer IngelheimNCT04846868 Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)Schizophreniacompleted620
2024-09-17P3AbbVie ABBVNCT04903626 Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment WHepatitis C Virus (HCV)completed286
2024-09-17P3Janssen Research & Development, LLCNCT06143878 A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisPlaque Psoriasisactive not recruiting774
2024-09-18P1/P2TransgeneNCT03260023 Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M CancersHPV-Related Carcinoma; HPV-Related Cervical Carcinoma; HPV-Related Anal Squamous Cell Carcinoma; HPVactive not recruiting143
2024-09-18 est.P2Biogen BIIBNCT04079088 Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)Relapsing Multiple Sclerosiswithdrawn
2024-09-18P3EMD Serono Research & Development Institute, Inc.NCT04459715 A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants WSquamous Cell Carcinoma of the Head and Neckterminated730
2024-09-18P3Janssen Research & Development, LLCNCT05455684 A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate ResponseDepressive Disorder, Major; Anhedoniacompleted513
2024-09-18P2Lallemand Health SolutionsNCT05755256 The Impact of Probiotics on Skin Hydration in Youth with Mild AcneAcne Vulgaris; Hydration Acnecompleted58
2024-09-18P3BayerNCT05915026 A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a ContrastContrast Enhancement in Magnetic Resonance Imaging; Childrencompleted105
2024-09-18P2Biosion, Inc.NCT05932654 POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic DermatitisAtopic Dermatitiscompleted22
2024-09-18P1/P2BioNTech SE BNTXNCT06069778 Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic AdenocarcinomaPancreatic Cancerterminated1
2024-09-19P3Corcept Therapeutics CORTNCT04308590 A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal AdenomasHypercortisolismcompleted137
2024-09-19P3Cristcot HCA LLCNCT04469686 Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate SuppositoriesUlcerative Proctitiscompleted200
2024-09-19P3Bio Sidus SANCT05843916 Switch Over Study of Biosimilar Agalsidase Beta for Fabry DiseaseFabry Diseasecompleted20
2024-09-19P2Ono Pharmaceutical Co., Ltd.NCT06538272 Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer ReceivCIPN - Chemotherapy-Induced Peripheral Neuropathycompleted210
2024-09-20P3AbbVie ABBVNCT05368558 Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With SchizophreniaSchizophreniaterminated34
2024-09-20P3BioDlink Biopharm Co., Ltd.NCT05461339 TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular DegenerationNeovascular Age-related Macular Degenerationactive not recruiting488
2024-09-20 est.P1/P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05508659 A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid TumorsAdvanced Solid Tumorsunknown128
2024-09-20P2Bolt Biotherapeutics, Inc. BOLTNCT05954143 Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast CancerMetastatic Breast Cancer; HER2-positive Breast Cancerterminated11
2024-09-20P3Pfizer PFENCT06473519 A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.Respiratory Syncytial Virus (RSV)completed453
2024-09-20P3Colgate Palmolive CLNCT06954779 Arginine Plaque Metabolism Pilot Clinical StudyPlaque, Dentalcompleted20
2024-09-23P3AstraZeneca AZNNCT04851964 Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal PolyposisChronic Rhinosinusitis With Nasal Polypscompleted416
2024-09-23P1/P2Cytovation ASNCT05383170 A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic CancersAdvanced Head and Neck Squamous Cell Carcinoma; Advanced Breast Cancer; Advanced Melanomacompleted6
2024-09-23P3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT05520177 A Phase III Study for 601 Versus Ranibizumab in Patients With Vision LossBranch Retinal Vein Occlusioncompleted351
2024-09-23P3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05741528 An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEPSchizophreniacompleted75
2024-09-23P3Abbisko Therapeutics Co, LtdNCT05804045 Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)Tenosynovial Giant Cell Tumor; Pigmented Villonodular Synovitis; Giant Cell Tumor of Tendon Sheathactive not recruiting94
2024-09-24P3NovoCure GmbH NVCRNCT02973789 Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) FollNonsmall Cell Lung Cancer; NSCLCcompleted291
2024-09-24P2FluidAI MedicalNCT04582708 Use of NERv's Inline Device as an Early Diagnostic Method for Postoperative ComplicationsAnastomotic Leak; Fistula; Postoperative Leak; Postoperative Pancreatic Fistula; POPFcompleted316
2024-09-24P2Aardvark Therapeutics, Inc. AARDNCT05153434 A Study of Oral ARD-101 in Patients With Prader-Willi SyndromePrader-Willi Syndromecompleted19
2024-09-24P3Merck Sharp & Dohme LLC MRKNCT05226598 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With MetastMetastatic Non-Small Cell Lung Cancerterminated739
2024-09-24P2Fujian Shengdi Pharmaceutical Co., Ltd.NCT05966272 Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes SubjectsType 2 Diabetescompleted199
2024-09-24P2/P3POLYSAN Scientific & Technological Pharmaceutical CompanyNCT06183242 Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic CholestasisCholestasis, Intrahepaticcompleted328
2024-09-25P1/P2Oncternal Therapeutics, IncNCT03088878 A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid MalignanciesB-cell Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Marginal Zonecompleted95
2024-09-25P3Biohaven Pharmaceuticals, Inc. BHVNNCT05337553 A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular AtrophySpinal Muscular Atrophy; Neuromuscular Diseases; SMAactive not recruiting269
2024-09-25P2Takeda TAKNCT05814016 A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal SurgerySleep Apneaterminated41
2024-09-25P3Vifor Fresenius Medical Care Renal PharmaNCT05885737 Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe PruritusUremic Prurituscompleted260
2024-09-25P3NewAmsterdam Pharma NAMSNCT06005597 Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying TherapiesDyslipidemias; Hypercholesterolemia; Familial Hypercholesterolemia; ASCVD; High Cholesterolcompleted407
2024-09-25P2HysensBio Co., LtdNCT06264453 A Study to Evaluate the Efficacy and Safety of KH001 in Patients with Dentin HypersensitivityDentin Hypersensitivitycompleted171
2024-09-25P2Shanghai Longwood Biopharmaceuticals Co., Ltd.NCT07186387 Study of LW402 in Moderate-to-Severe Atopic DermatitisAtopic Dermatitis (AD)completed144
2024-09-26P2Novo Nordisk A/S NVONCT02616562 Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone TreGrowth Hormone Disorder; Growth Hormone Deficiency in Childrencompleted76
2024-09-26P1/P2Hoffmann-La RocheNCT03280563 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative BreastBreast Neoplasmscompleted144
2024-09-26P1/P2Achilles Therapeutics UK LimitedNCT04032847 ATL001 in Patients With Advanced Unresectable or Metastatic NSCLCAdvanced Non Small Cell Lung Cancerterminated27
2024-09-26P1/P2ApcinteX LtdNCT04073498 The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)Hemophilia a; Hemophilia Bcompleted39
2024-09-26P2Windtree TherapeuticsNCT04325035 The Safety and Efficacy of Istaroxime for Pre-Cardiogenic ShockCardiogenic Shockcompleted90
2024-09-26P2Hope Medicine (Nanjing) Co., LtdNCT05101317 A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated PainEndometriosiscompleted142
2024-09-26P3NewAmsterdam Pharma NAMSNCT05142722 Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying TherapiesDyslipidemias; High Cholesterol; Hypercholesterolemia; Familial Hypercholesterolemia; Atheroscleroticompleted2530
2024-09-26P2PTC Therapeutics PTCNCT05349721 Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALSAmyotrophic Lateral Sclerosisterminated336
2024-09-26P2Cardior Pharmaceuticals GmbHNCT05350969 Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial InfarctionMyocardial Infarction, Acute; Heart Failure, Left Sidedcompleted294
2024-09-26P2Janssen Research & Development, LLCNCT06049017 A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative ColitisColitis, Ulcerativecompleted252
2024-09-26P2CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT06226090 A Study of TG103 Injection in the Management of Non-diabetic Overweight or ObesityObesity; Overweightcompleted314
2024-09-26P3CanSino Biologics Inc.NCT06226714 A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year OldsMeningococcal Meningitisactive not recruiting840
2024-09-27P3Merck Sharp & Dohme LLC MRKNCT04776148 Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-79Colorectal Neoplasmscompleted563
2024-09-27P2Thiogenesis Therapeutics, Inc. TTIPFNCT05212662 Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19COVID-19; COVID-19 Acute Respiratory Distress Syndromewithdrawn
2024-09-27P2AkesoNCT05227651 AK104 in Neoadjuvant Treatment of Cervical CancerCervical Cancercompleted14
2024-09-27P2/P3ACADIA Pharmaceuticals Inc. ACADNCT05523895 Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum DisorderIrritability Associated With Autism Spectrum Disordercompleted237
2024-09-27P3Tonghua Anrate Biopharmaceutical Co., Ltd.NCT06911554 A Study of Recombinant Human Albumin Injection to Treat Hypoalbuminemia in Cirrhotic Patients With AscitesHepatic Ascitescompleted416
2024-09-27P2Shenzhen Sciencare Medical Industries Co., Ltd.NCT07333638 Phase II Clinical Study on the Efficacy and Safety of Naltrexone Implant in Patients With Alcohol Use DisorderAUDcompleted210
2024-09-27P3Shanghai Xin Huanghe Pharmaceutical Co., Ltd.NCT07790159 Budesonide/Formoterol Inhalation Powder in Adults With AsthmaAsthmacompleted338
2024-09-29P1/P2Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.NCT04563533 Clinical Trial of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)Acute Gastroenteritiscompleted580
2024-09-29P2Novartis Pharmaceuticals NVSNCT04864392 Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee OsteoarthritisOsteoarthritisterminated576
2024-09-29P3Evopoint Biosciences Inc.NCT05204563 Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumoniacompleted450
2024-09-30P1/P2Seagen Inc.NCT03310957 Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast CancerTriple Negative Breast Neoplasmscompleted185
2024-09-30P2TaiRx, Inc.NCT03600233 Study of CVM-1118 for Patients With Advanced Neuroendocrine TumorsNeuroendocrine Tumors; Pancreatic Neuroendocrine Tumor; Gastro-enteropancreatic Neuroendocrine Tumoractive not recruiting34
2024-09-30P1/P2Microvascular Therapeutics, LLCNCT03882359 An Ascending Dose Comparison of MVT-100 to Definity in Healthy VolunteersHeart Diseasescompleted16
2024-09-30P3Eurofarma Laboratorios S.A.NCT03936933 Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast CancerBreast Cancerterminated6
2024-09-30P1/P2Taiho Oncology, Inc.NCT04657081 Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)Acute Myeloid Leukemiaactive not recruiting101
2024-09-30P3MeiraGTx Ocular UK Ltd MGTXNCT04671433 Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR GeneX-Linked Retinitis Pigmentosacompleted105
2024-09-30P1/P2Famewave Ltd.NCT04731467 A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid TumorsSolid Tumor; Non Small Cell Lung Cancer; Pancreatic Cancer; Ovarian Cancer; Papillary Thyroid Cancercompleted79
2024-09-30 est.P3Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.NCT04852068 A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells)Rabies Vaccine Adverse Reaction; Safety and Efficacyunknown2480
2024-09-30 est.P2Hallux, Inc.NCT05135910 To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of OnychomycosisOnychomycosis of Toenailunknown35
2024-09-30P3Stealth BioTherapeutics Inc.NCT05162768 Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)Mitochondrial Myopathies; Mitochondrial Pathology; Mitochondrial DNA Mutation; Mitochondrial Diseasecompleted102
2024-09-30 est.P2Shanghai Kechow Pharma, Inc.NCT05263453 HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K MutationMelanomaunknown104
2024-09-30 est.P3Daewoong Pharmaceutical Co. LTD.NCT05466643 A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes MellitusType 2 Diabetes Mellitusunknown240
2024-09-30 est.P2Shanghai Henlius BiotechNCT05513573 Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line TreatmNasopharyngeal Carcinoma by AJCC V8 Stageunknown75
2024-09-30P2/P3Shanghai Jiaolian Drug Research and Development Co., LtdNCT05555706 Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast CancerTriple Negative Breast Cancer (TNBC)completed62
2024-09-30P2GuerbetNCT05590884 Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of AgeCentral Nervous System Diseases; Pediatric Disorder; Body Indicationcompleted36
2024-09-30 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT06006104 Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate CancerAdvanced Prostate Cancerunknown49
2024-09-30 est.P3Apurano Pharmaceuticals GmbHNCT06071936 Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral NeuropathyPain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Neuropathic Pain; Peripheraunknown558
2024-09-30 est.P3Apurano Pharmaceuticals GmbHNCT06071949 Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any GenesisPain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Neuropathic Pain; Central Nunknown558
2024-09-30 est.P3Apurano Pharmaceuticals GmbHNCT06071962 Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back PainPain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Back Pain; Lower Back Pain;unknown558
2024-09-30 est.P3Apurano Pharmaceuticals GmbHNCT06071975 Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic PolyneuropathyPain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Diabetes; Diabetic Neuropatunknown558
2024-09-30 est.P3Apurano Pharmaceuticals GmbHNCT06071988 Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral NeuropathyPain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Neuropathic Pain; Peripheraunknown558
2024-09-30 est.P3Apurano Pharmaceuticals GmbHNCT06072001 Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any GenesisPain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Neuropathic Pain; Central Nunknown558
2024-09-30 est.P3Apurano Pharmaceuticals GmbHNCT06072560 Efficacy and Tolerability of AP707 in Patients With Chronic Back PainPain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Back Pain; Lower Back Pain;unknown558
2024-09-30 est.P3Apurano Pharmaceuticals GmbHNCT06072573 Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic PolyneuropathyPain; Pain Syndrome; Pain, Chronic; Chronic Pain; Chronic Pain Syndrome; Diabetes; Diabetic Neuropatunknown558
2024-09-30P2/P3Pfizer PFENCT06079320 A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) InfectionRespiratory Syncytial Virus Infectionterminated16
2024-09-30P2Endo USA Inc., a Keenova Therapeutics CompanyNCT06169319 A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)Plantar Fasciitiscompleted231
2024-09-30P2AstraZeneca AZNNCT06173570 A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With DyslipidemiaDyslipidemiacompleted428
2024-09-30P2Dexa Medica GroupNCT06497439 Efficacy and Safety of Silfamin for Common ColdCommon Cold; Sore-throatcompleted60
2024-09-30P2Dexa Medica GroupNCT06510257 Safety and Efficacy Reconyl for Cough With/Without Sore ThroatCoughcompleted60
2024-09-30 est.P1/P2Synthonics IncNCT06570941 Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg SyndromeRestless Legs Syndromeunknown10

← 2024-08 | 2024-10 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.